Quotes 5-day view Delayed Nasdaq
01/11/2021
01/12/2021
01/13/2021
01/14/2021
01/15/2021
Date
54.42(c)
53.57(c)
53.31(c)
54.46(c)
53.66(c)
Last
888 712
708 530
629 349
555 279
756 059
Volume
+2.43%
-1.56%
-0.49%
+2.16%
-1.47%
Change
Sales 2020
444 M
-
-
Net income 2020
-290 M
-
-
Net cash position 2020
427 M
-
-
P/E ratio 2020
-29,1x
Yield 2020
-
Sales 2021
677 M
-
-
Net income 2021
-154 M
-
-
Net cash position 2021
353 M
-
-
P/E ratio 2021
-54,3x
Yield 2021
-
Capitalization
8 531 M
8 531 M
-
EV / Sales 2020
18,3x
EV / Sales 2021
12,1x
Nbr of Employees
580
Free-Float
99,6%
ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on...
Notations Surperformance© of ACADIA Pharmaceuticals Inc.
Trading Rating :
Investor Rating :
All news about ACADIA PHARMACEUTICALS INC.
News in other languages on ACADIA PHARMACEUTICALS INC.
Analyst Recommendations on ACADIA PHARMACEUTICALS INC.
Canada's RBC turns heads in U.S. with wealth management recruitment push
Chart ACADIA PHARMACEUTICALS INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ACADIA PHARMACEUTICALS INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
20
Average target price
61,70 $
Last Close Price
53,66 $
Spread / Highest target
34,2%
Spread / Average Target
15,0%
Spread / Lowest Target
-21,7%
Please enable JavaScript in your browser's settings to use dynamic charts.